.
Camelid immunization is a critical step in nanobody (VHH) discovery, enabling the generation of diverse, high-affinity heavy-chain antibodies (HcAbs). A well-designed immunization strategy directly impacts the quality of downstream VHH libraries and the success of binder discovery.
Binder Discovery
Application-Specific Nanobody Discovery
We provide end-to-end camelid immunization services using alpacas, llamas, or camels. Our optimized immunization protocols, combined with flexible antigen formats and advanced monitoring methods, ensure robust immune responses and high-quality PBMC samples for nanobody discovery.
Our standard immunization program spans approximately 49 days, designed to achieve strong and sustained immune responses.
Four antigen injections at two-week intervals
Three blood collection timepoints for immune monitoring
PBMC collection for downstream library construction
This approach ensures efficient maturation of antigen-specific VHH responses and supports high-quality nanobody discovery.

Figure 1. Animal Immunization and Blood Collection
(a) Alpaca immunization procedure. (b) Blood collection from alpaca. (c) 49-day immunization timeline. Black arrows indicate injection days (Days 0, 14, 28, 42), and droplet icons represent blood collection (Days 0, 21, 35, 49). Day 0 serum is used as a negative control, while samples collected after immunization are used to measure immune response by titer testing.
We support a wide range of immunogen formats to address diverse target types:
Recombinant proteins
Peptides
Whole cells
Virus-like particles (VLPs)
LNP-mRNA
Adenoviral or other viral vector-based antigens
Flexible antigen formats enable successful immunization of challenging targets, including membrane proteins and poorly immunogenic molecules.
Our immunization workflows are fully customizable based on target characteristics and project goals.
| Immunization Species | Adjuvant Options |
| Alpaca Llama Camel |
Freund’s adjuvant Proprietary water-soluble adjuvants |
| Injection Routes | Strategy Optimization |
| Subcutaneous Intramuscular Nasal administration |
We optimize antigen format, dosing schedule, and delivery method to maximize immune response and nanobody diversity. |
We monitor immune responses throughout the immunization process to ensure successful antibody generation.
ELISA-based serum titer analysis
Flow cytometry (FACS) analysis
VHH-specific detection assays
These methods allow real-time evaluation of antibody development and optimization of immunization strategies.
Clients will receive:
Pre-immune serum
Immune serum samples
Isolated PBMCs for library construction
Serum titer and immune response data
Comprehensive project report
Optional services:
Nanobody library construction and screening
High-Quality, Naïve Animals
All animals are verified to have no prior exposure to target antigens, ensuring clean immune backgrounds and unbiased antibody generation.

Figure 2. Our dedicated 40-acre farm houses high-quality alpacas and llamas imported from South America. With expert breeding and veterinary care, we ensure optimal animal health and project confidentiality.
Customized Immunogen Design
We tailor each antigen to your target and application, offering custom design and preparation of mRNA, VLPs, fusion proteins, and more. Every format is optimized to improve immunogenicity, preserve structural integrity, and ensure reliable downstream VHH discovery.
Proprietary Adjuvant Technology
Our camelid-optimized adjuvants enhance immune responses and boosts HcAb titer while maintaining antigen integrity and minimizing toxicity.

Figure 3. Serum titers following alpaca immunization with a camelid immune adjuvant and antigen mixture. The left panel shows total IgG titers after four immunizations; the right panel shows VHH titers. The X-axis represents serum dilution, and the Y-axis indicates OD values measured by ELISA.
Advanced Immune Monitoring
Integrated ELISA and FACS-based assays enable precise monitoring of antibody development.
Proprietary VHH Detection Antibody
Our in-house detection antibody allows sensitive and specific quantification of VHH titers without cross-reactivity.

Figure 4. Left: Our AlpHcAb detection antibody demonstrates high affinity across diverse VHH sequences. Right: It shows strong specificity for VHHs without binding other alpaca or cross-species IgGs.
Seamless Integration with Discovery Platforms
Direct compatibility with phage display / yeast display library construction and screening workflows.
|
Genus |
Common Name |
Scientific Name |
% Heavy-chain Antibodies vs. Total Antibodies |
% with Extra Disulfide Bonds |
V Region Homology to Human (%) |
|
Camel |
Bactrian Camel
|
Camelus bactrianus |
~70% |
~80% |
65~70% |
|
Lama |
Llama
|
Lama glama |
~45% |
~10% |
>80% |
|
Alpaca |
Alpaca
|
Vicugna pacos |
~45% |
~10% |
>80% |
|
Package |
Service Step |
Deliverables |
Timeline |
|
Optional |
Immunogen preparation |
Prepared immunogen and QC report |
2–6 weeks |
|
Basic |
Animal immunization & monitoring |
Serum samples, PBMCs, project report |
~7 weeks |